Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo losartan Clear all

Conditions: Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions: Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hamstring Injury
Interventions: Losartan, Placebo; Drug
Lead sponsor: James J. Irrgang; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infection, HIV Infections
Interventions: Losartan, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: Losartan, Captopril, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cystic Fibrosis
Interventions: Losartan, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 12 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hypertension
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Inflammation
Interventions: Omega-3 fish oil, Losartan, Corn Oil (Fish oil Placebo), Cellulose Based (Losartan Placebo); Dietary Supplement · Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 70 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Gainesville, Florida • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions: Losartan, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 13
States / cities: Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more

Conditions: Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions: Losartan, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Radiation Induced Fibrosis
Interventions: Losartan 25 milligram capsule, Placebo; Drug
Lead sponsor: Shaw Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Edwards, Colorado

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Active Control, INV-144; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Garden Grove, California • La Mesa, California • Northridge, California + 15 more

Conditions: Hypertension
Interventions: Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 88
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more

Conditions: Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour), Hypertension
Interventions: Losartan, Allopurinol, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 21 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Green Bay, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 1 more

Conditions: Kidney Disease, Proteinuria
Interventions: Losartan 100mg, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Conditions: Posttraumatic Stress Disorder
Interventions: losartan, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 6
States / cities: La Jolla, California • Washington D.C., District of Columbia • Bethesda, Maryland + 3 more

Conditions: SARS-CoV-2 Infection
Interventions: Losartan, Placebo; Drug
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Femoroacetabular Impingement
Interventions: Fisetin, Placebo; Drug
Lead sponsor: Steadman Philippon Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Interventions: Sildenafil, Losartan, Sildenafil and Losartan, Placebo Oral Tablet; Drug
Lead sponsor: Alicia Gerke; Other
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions: Losartan, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: NAFLD - Nonalcoholic Fatty Liver Disease
Interventions: Losartan potassium, Placebo losartan capsule; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: losartan, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Hypertension
Interventions: Losartan, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Sarcopenia
Interventions: Losartan, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 70 Years to 100 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study

Treatment of Supine Hypertension in Autonomic Failure

Losartan for Patients With COVID-19 Requiring Hospitalization

Losartan for Patients With COVID-19 Not Requiring Hospitalization

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Study of Cardiovascular Disease and Obstructive Sleep Apnea

Angiotensin II Blockade for Chronic Allograft Nephropathy

A Controlled Trial of Losartan in Posttraumatic Stress Disorder

COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

Efficacy of Losartan in Preventing Progression of COPD

Losartan for the Treatment of Pediatric NAFLD

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Secondhand Tobacco Smoke and Cardiovascular Disease

A Study of Muscle Strength Maintenance in Older Adults